News|Articles|May 27, 2025

Conference Recap: 6 Key Trials From American Thoracic Society 2025

View conference highlights from HCPLive’s coverage of the American Thoracic Society (ATS) International Conference 2025.

The American Thoracic Society’s (ATS) International Conference took place in San Francisco, California, from May 18-21, 2025. Coined as the home of pulmonary, critical care, and sleep professionals, the 4-day conference featured the latest advances in each of these spaces, including updates on key topics in asthma, chronic obstructive pulmonary disease (COPD), lung cancer, sepsis, acute respiratory distress, sleep apnea, and more.

Related to this article

November 11th, 2026

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

November 6th, 2026

Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.

November 6th, 2026

Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.

November 9th, 2026

The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.

November 10th, 2026

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

November 9th, 2026

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

November 9th, 2026

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

November 9th, 2026

The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.